Grant Life Sciences Terminates Negotiations with Diagnostic Technologies Ltd. to Develop and Commercialize Grant Life Sciences' Serum-Based Cervical Cancer-Diagnostic Platform
Published: Aug 13, 2007
LOS ANGELES--(BUSINESS WIRE)--Grant Life Sciences (‘Grant’) Inc. (OTC BB: GLIF) announced today that it has decided to terminate further negotiations with Israel-based Diagnostic Technologies Ltd. (DTL) related to Grant’s serum-based cervical cancer-diagnostic technology (U.S. Patent No. 6,743,593) as announced in April 2006, and subsequently extended on October 15, 2006. An extension of the MOU between Grant and DTL was made necessary because DTL’s business activities were significantly hindered as a result of the 2006 Israel/Lebanon conflict, which occurred between July 12 and August 14, 2006.